Nabriva Therapeutics plc Quarterly Income Tax Expense (Benefit) in USD from Q1 2015 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Nabriva Therapeutics plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2015 to Q2 2023.
  • Nabriva Therapeutics plc Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $0.000, a 100% decline year-over-year.
  • Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2022 was $1.57M, a 220% increase from 2021.
  • Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2021 was $490K, a 253% increase from 2020.
  • Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2020 was $139K, a 37.6% increase from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $0 -$385K -100% Apr 1, 2023 Jun 30, 2023 10-Q 2023-10-19
Q4 2022 $1.57M $309K +$363K Oct 1, 2022 Dec 31, 2022 10-K 2023-04-17
Q3 2022 $1.21M $520K +$772K Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $433K $385K -$221K -36.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-19
Q1 2022 $654K $354K +$164K +86.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q4 2021 $490K -$54K +$6K +10% Oct 1, 2021 Dec 31, 2021 10-K 2023-04-17
Q3 2021 $484K -$252K -$180K -250% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $664K $606K +$487K +409% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 $177K $190K +$38K +25% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $139K -$60K -$81K -386% Oct 1, 2020 Dec 31, 2020 10-K 2023-04-17
Q3 2020 $220K -$72K -$43K -148% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $263K $119K +$164K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $99K $152K -$2K -1.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $101K $21K +$280K Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$179K -$29K +$122K +80.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$301K -$45K +$3K +6.25% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$304K $154K -$352K -69.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $48K -$259K -$360K -356% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $408K -$151K -$2.02M -108% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 $2.43M -$48K +$919K +95% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 $1.51M $506K +$157K +45% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 $1.36M $101K +$772K Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 $583K $1.87M +$1.84M +6586% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$1.26M -$967K -$955K -7958% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$306K $349K +$366K Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$672K -$671K -$466K -227% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$206K $28K +$282K Jul 1, 2016 Sep 30, 2016 10-K 2018-03-16
Q2 2016 -$488K -$12K -$14K -700% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-16
Q1 2016 -$474K -$17K -$29K -242% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-16
Q4 2015 -$445K -$205K Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 -$254K Jul 1, 2015 Sep 30, 2015 10-K 2017-03-24
Q2 2015 $2K Apr 1, 2015 Jun 30, 2015 10-K 2017-03-24
Q1 2015 $12K Jan 1, 2015 Mar 31, 2015 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.